Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma
Open Access
- 1 January 2000
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 43 (1) , 94-102
Abstract
Objective Type II mixed cryoglobulinemia (type II MC) is often characterized by features of indolent B cell lymphoma (IBCL) found on pathologic examination of bone marrow, whereas the clinical evidence does not indicate a neoplastic disorder. To better address the issue of indolent malignant versus nonmalignant bone marrow lymphoproliferation underlying type II MC, molecular analyses of B cell clonality were performed in the present study, in conjunction with clinical and pathologic characterization. Methods Polymerase chain reaction DNA amplification of immunoglobulin heavy chain genes was performed in bone marrow biopsy specimens obtained from 15 selected patients with type II MC, all infected with hepatitis C virus. Five of them had also developed overt B cell lymphoma (OBCL) during followup. Bone marrow features were consistent with IBCL in 9 of the 15 patients (group 1) and with reactive lymphoplasmacytosis in 6 of the 15 (group 2). Results An oligoclonal B cell expansion was detected in 6 of 9 baseline bone marrow lesions from group 1 patients (biclonal or monoclonal expansion in the remaining 3 cases), and in 6 of 6 from group 2 patients. OBCL was always monoclonal. Selected lesions were analyzed by clonospecific hybridization and by cloning and sequence analysis in patients who had developed OBCL at followup. In 4 of 5 cases, OBCL did not originate from the dominant B cell clones that were overexpanded in the putative neoplastic baseline bone marrow lesions. OBCL clones showed significant homology with rheumatoid factor database sequences. Conclusion Based on the present results, as well as on evidence from previous studies of liver lesions, oligoclonal non‐neoplastic B cell proliferation in the course of chronic infection–related inflammation appears to be the key feature of type II MC. Of note, molecular evidence from target tissues supports the clinical findings both at the time of type II MC diagnosis and in cases of OBCL complication. Bone marrow pathologic findings resembling those of IBCL should thus be considered in the light of clinical and molecular evidence.Keywords
This publication has 35 references indexed in Scilit:
- Case 3-1999New England Journal of Medicine, 1999
- Gapped BLAST and PSI-BLAST: a new generation of protein database search programsNucleic Acids Research, 1997
- Rarity of microsatellite genomic instability in B‐cell non‐Hodgkin's lymphomas in hepatitis C virus‐infected patientsBritish Journal of Haematology, 1997
- Differences in mutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germ‐line gene usageEuropean Journal of Immunology, 1997
- Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndromeArthritis & Rheumatism, 1997
- Comparison of rheumatoid factors of rheumatoid arthritis patients, of individuals with mycobacterial infections and of normal controls: evidence for maturation in the absence of an autoimmune responseEuropean Journal of Immunology, 1996
- Mixed cryoglobulinemia as a possible preneoplastic disorderArthritis & Rheumatism, 1995
- Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptideJournal of Immunological Methods, 1994
- CDR3 length in antigen-specific immune receptors.Journal of Experimental Medicine, 1994
- A Role for Hepatitis C Virus Infection in Type II CryoglobulinemiaNew England Journal of Medicine, 1992